^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    GTAEXS617

    i
    Other names: GTAEXS617, GTAEXS-617
    Associations

    News

    Trials
    Company:
    Exscientia
    Drug class:
    CDK7 inhibitor
    Related drugs:
    Associations

    News

    Trials
    over1year
    ELUCIDATE: Study to Assess GTAEXS617 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=170, Recruiting, Exscientia AI Limited
    New P1/2 trial • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • CDK6 (Cyclin-dependent kinase 6) • CD4 (CD4 Molecule)
    |
    HER-2 negative
    |
    GTAEXS617